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Background: Human Papilloma Virus (HPV) infection is the major cause of cervical cancer worldwide. With limited
data available on HPV prevalence in the Arab countries, this study aimed to identify the prevalence and genotypic
distribution of HPV in the State of Qatar.
Methods: 3008 cervical samples, exclusively of women with Arabic origin residing in Qatar were collected from the
Women’s Hospital and Primary Health Care Corporation in Doha, State of Qatar. HPV DNA detection was done
using GP5+/6+ primers based real time-polymerase chain reaction (RT-PCR) assay followed by the usage of HPV
type specific primers based RT- PCR reactions and Sanger sequencing for genotype identification.
Results: Similar prevalence rates of HPV infection was identified in both Qatari and non-Qatari women at 6.2% and
5.9% respectively. HPV prevalence rate of 5.8% and 18.4% was identified in women with normal cytology and in
women with abnormal cytology respectively. HPV 81, 11 and 16, in decreasing order were the most commonly
identified genotypes. HPV 81 was the most frequent low-risk genotype among women with both normal (74.0%)
and abnormal (33.3%) cytology. HPV 16 (4.6%) was identified as the predominant high-risk HPV genotype among
women with normal cytology and HPV 16, HPV 18, and HPV 56 (22.2% each) were the most common identified
high-risk genotypes in women with abnormal cytology.
Conclusions: The overall HPV prevalence in Arab women in Qatar was identified as 6.1% with an increased HPV
prevalence seen in women with abnormal cytology results and no significant trends seen with age. In contrast to
Western countries, we report a varied genotypic profile of HPV with a high prevalence of low-risk HPV genotype 81
among the Arab women residing in Qatar.
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In developing countries, cervical cancer is the most com-
mon cancer among women with more than 85% of the
global cervical cancer deaths occurring in these countries
[1,2]. Molecular epidemiological studies have shown that
Human Papillomavirus (HPV) infection represents the
major etiological factor of cervical cancer [3,4]. To date,* Correspondence: als2026@qatar-med.cornell.edu
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unless otherwise stated.more than 200 HPV genotypes have been identified and
characterized based on nucleotide sequence relatedness of
the L1 gene which codes for the major HPV capsid protein
[5]. Among these, based on their oncogenic potential via
associations with cervical cancer and precancerous lesions,
about 30 to 40 genotypes are divided into high-risk (HR)
genotypes that cause cervical neoplasia, and low-risk (LR)
HPV genotypes that cause mild dysplasia [5-7].
The prevalence of HPV infections in women within the
general population differs considerably between countries
and regions, as well as within regions, ranging from 1.6-
41.9% [8]. Very limited data is available on the prevalenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tural and sexual behaviors may differ from the more-well
reported Western countries [9,10]. Among the few pub-
lished studies, HPV prevalence has been reported between
0% and 25% in women with normal cytology and up to
98% in women with abnormal cytology in the Extended
Middle Eastern and North African (EMENA) countries
[8,10-12]. Additionally, in a previous pilot study in Qatar,
Al-Thani et al., identified a 64% prevalence of HPV in a
cohort of women at high-risk for the infection [13].
Qatar is an Arab State located in Western Asia. Recent
economic growth and globalization has resulted in a
large influx of foreign expatriates from Western, other
Middle Eastern, African and Asian countries leading to a
dynamic socio-economic environment which possibly
may affect social and sexual lifestyles in this country.
However, there is limited data to investigate how these
changes have affected the prevalence of sexually trans-
mitted diseases such as HPV among the general popula-
tion. Molecular epidemiological studies are warranted to
understand the current disease burden posed by the circu-
lating HPV genotypes and for predicting future projections
of sexually transmitted diseases and cervical cancer in the
population and within key sub-populations. Therefore, in
the present study, we identified the prevalence and geno-
typic distribution of HPV among Arab women, with nor-
mal or abnormal cytology, living in the state of Qatar. The
findings of this paper are critical towards estimation of
relevance and outcome of HPV vaccination and HPV
screening for cancer prevention in Qatar, both of which
are not currently practiced in this country.
Materials and methods
Ethical considerations, study population and sample
collection
This study was approved (Protocol no. - 10165/10) by
the Institutional Review Board (IRB) of the Weill Cornell
Medical College in Qatar (WCMCQ) and Hamad
Medical Corporation (HMC) Research Office, Doha,
Qatar. During March 2012-January 2013, a total of 3008
cervical samples, exclusively of women with Arabic ori-
gin (nationals of any of the 22 countries in the League of
Arab States) residing in Qatar were collected from
the women attending Women’s Hospital at HMC and
Primary Health Care Corporation in Doha, Qatar for
routine gynecological care/clinical symptoms. Inclusion
criteria included married, non-pregnant women attend-
ing the above clinics. Only married or previously mar-
ried women were considered in this study as Pap smear
tests for never married women are not culturally accept-
able. Women with known presence of cervical cancer
and immunocompromised patients were excluded from
this study. All samples fitting the inclusion criteria were
included.Cervical samples were collected in ThinPrep vials (BD
SurePath™) for Pap smear assay and molecular HPV typ-
ing. ThinPrep cytological smears were screened at HMC
and reported according to the Bethesda system for
reporting of cervical cytology [14]. For each woman,
other collated data include age, nationality, clinical his-
tory, and cytological diagnosis.
DNA extraction and detection of HPV infection by real
time PCR
Viral DNA from cervical samples was extracted by
QIAamp MinElute virus spin kit according to the manu-
facturer’s instructions (Qiagen, CA, USA). To determine
the presence of HPV-DNA, L1 consensus primers (GP5+:
5′- TTT GTT ACT GTG GTA GAT ACT AC -3′ and
GP6+: 5′- GAA AAA TAA ACT GTA AAT CATATT C -
3′) that amplify a conserved 150 bp sequence of the L1
open reading frame was used [15]. Human β-globin gene
primers (PCO3: 5′- ACA CAA CTG TGT TCA CTA GC -
3′ and PCO4: 5′- CAA CTT CAT CCA CGT TCA CC -
3′) were used [15] to ensure the DNA quality of the
samples.
Real-time polymerase chain reaction (RT-PCR) assay
was carried out in ABI 7500 (Applied Biosystems, CA,
USA) to detect HPV DNA using the following protocol:
2 μL extracted genomic DNA (5 ng/μL) was combined
with 12.5 μl of 2X SyberGreen (Applied Biosystems, CA,
USA) containing ROX as a passive reference along with
10 pmol (10 μM) each of forward and reverse primers
(GP5+ and GP6+ or PCO3 and PCO4) and the mixture
was made up to 25 μL volume with nuclease free water
(Ambion, CA, USA). The PCR amplification was initi-
ated at 95°C for 10 min and followed by 45 amplification
cycles (denaturation at 95°C for 20 sec, annealing at 50°C
for 30 sec and extension at 60°C for 30 sec).
All the samples were analyzed in duplicates on 96 well
plates (Applied Biosystems, CA, USA). A positive con-
trol (plasmid carrying cloned HPV L1 fragment) and a
negative control (nuclease free water) were included in
each amplification reaction. HPV positive samples were
detected by analyzing the amplicon dissociation curve
and samples showing a melting temperature (Tm) be-
tween 75°C and 80°C were considered as positive. PCR
products were also evaluated for β globin and L1 gene
bands on 2% agarose gel stained with ethidium bromide
and visualized with UV light.
HPV genotyping by RT-PCR kits and DNA sequencing
Identification of the infecting HPV genotype(s) in the
samples which tested positive for HPV DNA was done
using an RT-PCR based kit (Sacace Biotechnology,
Como, Italy), which tests for 12 high-risk HPV genotypes
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) and 2
low-risk HPV genotypes (6,11). The reactions were
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All samples, which tested positive for HPV infection
by RT-PCR, but where genotyping could not be assigned
on the basis of the typing method described above, were
subsequently subjected to sequencing (Genewiz Inc., NJ,
USA). PCR using GP5+/GP6+ primer set and same reac-
tion conditions as used during detection of HPV infec-
tion in cervical samples was used to generate amplicons.
In cases where the primary PCR yields were low, an add-
itional round of PCR using 2 ul of the primary PCR
product and the same primers was done to ensure
enough yields to perform direct sequencing. The PCR
products were purified using MinElute PCR Purification
Kit according to manufacturer’s instructions (Qiagen,
CA, USA). Purified products were sequenced using the
Sanger method (Genewiz, NJ, USA) with GP6+ primer.
The sequences were aligned using SeqMan Pro module
of Lasergene 10.0 software (DNASTAR, WI, USA). ForTable 1 Unadjusted and adjusted odd ratios (ORs) for HPV po
(CIs) according to selected descriptive characteristics among
Total no. women HPV positive, n
Age groups
16-24 136 (4.5) 7 (5.1)
25-34 756 (25.1) 44 (5.8)
35-44 919 (30.6) 51 (5.5)
45-54 835 (27.8) 54 (6.5)
≥55 362 (12.0) 26 (7.2)
Cytology results
Normal cytology 2959 (98.4) 173 (5.8)
Abnormal cytology 49 (1.6) 9 (18.4)
Clinical findings
Routine smear test 2401 (79.8) 142 (5.9)
Symptomatic results≠ 607 (20.2) 40 (6.6)
Nationality
Qatari 1404 (46.7) 87 (6.2)
Non-Qatari 1604 (53.3) 95 (5.9)
Nationality
Qatari 1404 (46.7) 87 (6.2)
Egyptian 465 (15.5) 26 (5.6)
Arabian peninsula$ 310 (10.3) 14 (4.5)
Fertile Crescent£ 566 (18.8) 37 (6.5)
North Africa# 95 (3.2) 7 (7.4)
East Africa^ 168 (5.6) 11 (6.5)
*p-value < 0.05.
$Arabian Peninsula excluding Qatar (KSA, Kuwait, Bahrain, UAE, Oman, Yemen).
£Fertile Crescent excluding Egypt (Iraq, Jordan, Lebanon, Palestine, Syria).
#North Africa (Morocco, Algeria, Tunisia, Libya and Mauritania).
^East Africa (Somalia, Djibouti, Sudan and Comoros).
≠Symptomatic results include: cervical erosion, genital warts, lower abdominal pain,
infertility, vaginal bleeding, vaginal discharge, vaginal spotting and vulva itching.genotyping, 35 bp sequences adjacent to the GP5+
primer-binding site was used for nucleotide-nucleotide
BLAST analysis (blastn) against known HPV genotype
sequences in the GenBank database (www.ncbi.nlm.nih.
gov/BLAST/). This 35 bp hyper-variable region of the
L1 gene has been shown to be sufficient for distinguish-
ing between various HPV genotypes [16]. Genotypes
were assigned only when there was a 100% similarity be-
tween the 35 bp query and the subject sequence.
Statistical analysis
Statistical analyses were performed using IBM SPSS ver-
sion 21.0. Sample characteristics including age, cytology
results, clinical findings and nationality were summa-
rized using frequency distributions to generate the num-
bers and percentages (Table 1). The prevalence of HPV
positivity by each of the above mentioned characteristics
was assessed using the chi-squared test (Table 1). Un-
adjusted and adjusted odds ratios (ORs) for HPV positivitysitivity and their corresponding 95% confidence intervals
3008 women in Qatar
(%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
1 1
1.14 (0.50-2.58) 1.20 (0.53-2.73)
1.08 (0.48-2.44) 1.15 (0.51-2.59)
1.27 (0.57-2.86) 1.36 (0.60-3.07)
1.43 (0.60-3.37) 1.49 (0.63-3.54)
1 1
3.62 (1.73-7.59)* 3.68 (1.75-7.75)
1 1
1.12 (0.78-1.61) 1.15 (0.80-1.65)
1 1
0.95 (0.71-1.29) 1.00 (0.73-1.36)
1 –
0.90 (0.57-1.41)
0.72 (0.40-1.28)
1.06 (0.71-1.58)
1.20 (0.54-2.68)
1.06 (0.55-2.03)
menorrhagia, pelvic pain, post coital bleeding, primary infertility, secondary
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lated according to the selected characteristics summarized
in Table 1, using bivariate and multivariable logistic re-
gressions, respectively. The prevalence of HPV along with
the 95% CI among Qatari and non-Qatari samples was
plotted by age group (Figure 1). Chi-squared test for trend
was used to assess whether there is an increasing or de-
creasing trend in the proportion of HPV positivity by age
among Qatari and non-Qatari women. A p-value of less
than 0.05 was considered significant. The distribution of
HPV genotypes was summarized using frequency distribu-
tion and stratified by cytology results (abnormal versus
normal cytology) (Table 2).
Results
Demographic and clinical characteristics of the study
population
Samples were collected from women visiting hospital/
clinic for routine gynecological care or for different clin-
ical symptoms such as vaginal discharge, vaginal bleed-
ing, genital warts, vulva itching, lower abdominal &
pelvic pain, infertility, menorrhagia, among others. The
population cohort analyzed in this study was recruited
to reflect the general Arab women population in Qatar.
This is supported by the clinical findings for subjects
summarized in Table 1, which shows that 79.8% (n = 2401)
of the women underwent routine gynecologic care and
only 20.2% (n = 607) were symptomatic. Additionally,
based on Pap smear test, 98.4% (n = 2959) of the women
had normal cytology results without any lesions. A minor-
ity of women (n = 49, 1.6%) had abnormal cytology results
with either low-grade squamous intraepithelial lesion
(LGSIL) indicating mild dysplasia or high-grade squamous
intraepithelial lesion (HGSIL) indicating severe intrae-
pithelial neoplasia.Figure 1 Prevalence of HPV by age groups and nationality and their
in Qatar.All age groups were well represented as seen in Table 1.
The age range across the sample was 16–84 years with a
mean age of 41.6 years (SD = 10.9). 46.7% (n = 1404) of
the women in the sample were Qataris with the rest be-
longing to other Middle Eastern, North and East African
countries in the League of Arab States (Table 1), which
is reflective of the make-up of the general Arab women
population in Qatar.
HPV DNA prevalence in Arab women
The overall HPV prevalence in Arab women in Qatar
was 6.1% (n = 182). Similar prevalence rates of HPV in-
fection was identified in both Qatari and non Qatari
women at 6.2% (n = 87, 95% CI: 4.9-7.5%) and 5.9% (n = 95,
95% CI: 4.8-7.1%) respectively (Table 1). Among the non-
Qatari Arab women, HPV prevalence was highest in
women originating from African and fertile crescent coun-
tries (North Africa: 7.4% (n = 7, 95% CI: 2.0-12.7%), Fertile
Crescent excluding Egypt: 6.5% (n = 37, 95% CI: 4.5-8.6%)
and East Africa: 6.5% (n = 11, 95% CI: 2.8-10.3%)) followed
by a 5.6% rate in Egyptian women and (n = 26, 95% CI:
3.5-7.7%) and a lower prevalence of 4.5% (n = 14, 95% CI:
2.2-6.8%) in women from the Arabian peninsula excluding
Qatar (Table 1).
HPV prevalence was identified as 5.8% (n = 173, 95%
CI: 5.0-6.7%) among women with normal cytology. Among
women with abnormal cytology, the overall HPV preva-
lence was detected as 18.4% (n = 9, 95% CI: 7.1-29.6%)
(Table 1) which included 36 samples with LGSIL of which,
8 were HPV positive and 13 samples with HGSIL of
which, 1 was positive for HPV. This increased association
between HPV prevalence and abnormal cytology results
was also found to be statistically significant (OR: 3.68, 95%
CI: 1.75-7.75%). However, no significant difference was ob-
served in HPV prevalence in women coming for routinecorresponding 95% confidence interval (CI) among Arab women
Table 2 The distribution of HPV types among HPV DNA positive cervical samples among Arab women in Qatar
General Arab population in Qatar
Normal cytology (n = 2959) Abnormal cytology (n = 49) All (n = 3008)
HPV type Single Double Multiple Unknown Total Percent Single Double Multiple Unknown Total Percent Total Percent
HPV positive 144 19 5 5 173 5.8 5 3 1 0 9 18.4 182 6.1
High-risk
16 4 2 2 – 8 4.62 0 1 1 – 2 22.22 10 5.49
18 0 0 3 – 3 1.73 0 2 0 – 2 22.22 5 2.74
31 1 2 1 – 4 2.31 0 1 0 – 1 11.11 5 2.74
33 1 2 1 – 4 2.31 0 0 0 – 0 0.00 4 2.19
35 0 1 1 – 2 1.15 0 0 0 – 0 0.00 2 1.09
39 0 1 1 – 2 1.15 0 0 0 – 0 0.00 2 1.09
45 2 3 0 – 5 2.89 0 0 0 – 0 0.00 5 2.74
51 0 1 1 – 2 1.15 0 0 1 – 1 11.11 3 1.64
52 1 0 0 – 1 0.57 0 0 0 – 0 0.00 1 0.54
56 0 4 1 – 5 2.89 1 1 0 – 2 22.22 7 3.84
58 1 0 1 – 2 1.15 1 0 0 – 1 11.11 3 1.64
59 4 1 1 – 6 3.46 0 0 0 – 0 0.00 6 3.29
Intermediate
risk
67 4 1 1 – 6 3.46 0 0 0 – 0 0.00 6 3.29
Low-risk
6 1 3 0 – 4 2.31 0 0 0 – 0 0.00 4 2.19
11 4 5 2 – 11 6.35 0 1 1 – 2 22.22 13 7.14
81 119 9 0 – 128 73.98 3 0 0 – 3 33.33 131 71.97
90 2 3 0 – 5 2.89 0 0 0 – 0 0.00 5 2.74
Note: Abnormal cytology includes LGSIL + HGSIL.
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0.80-1.65%).
HPV prevalence overall was found to be highest (7.2%)
in the age group >55 (n = 26, 95% CI: 0.63-3.54%) (Table 1).
Measured HPV prevalence was highest in the 25-34 age
group (n = 17, 7.1%, 95% CI: 3.8-10.4%) among Qatari
women, and in the age group >55 (n = 13, 8.5%, 95% CI:
4.0-13.0%) among non-Qatari women (Table 1). HPV
prevalence appeared to increase slightly with age in non-
Qatari women, while no such trend was seen in Qatari
women (Figure 1). However, by chi-squared trend ana-
lyses, no significant trends were found in HPV prevalence
versus age for either Qatari women or non-Qatari women.
Distribution of HPV genotypes in Arab women
The 182 cervical samples, which were identified as posi-
tive for HPV DNA, were further analyzed to identify the
infecting HPV genotype and were classified based on
their oncogenic potential as shown in Table 2. Among
HPV positive women, taking into account the total fre-
quency of occurrence of each specific genotype occur-
ring either as single/multiple infection (sum of frequencyof genotypes belonging to a specific risk category/total
number of women (182)), 84.0% (n = 153, 95% CI: 76.9-
88.3%) had at least one low-risk HPV genotype, 3.3%
(n = 6, 95% CI: 1.2-7.0%) had one intermediate-risk HPV
genotype, and 29.1% (n = 53, 95% CI: 22.6-36.3%) had at
least one high-risk HPV genotype (Table 2). Five samples
(2.7%; 95% CI: 0.9-6.3%) remained uncharacterized and
have been listed in Table 2 as unknown.
HPV 81 was the most frequent low-risk genotype
among women with both normal (n = 128, 74.0%; 95%
CI: 66.8-80.4%) and abnormal (n = 3, 33.3%; 95% CI: 7.5-
70.1%) cytology (Table 2). Women with HPV 81 geno-
type were at significantly less risk of showing abnormal
cytology than women with high-risk genotypes (OR:
0.13, 95% CI: 0.03-0.55), as described in Table 3. The
only intermediate-risk HPV genotype identified was HPV
67, which had a 3.5% (n = 6, 95% CI: 1.3-7.4%) prevalence
among women with normal cytology (Table 2). No cases
of HPV 67 were identified among women with abnormal
cytology. Meanwhile, HPV 16 (n = 8, 4.6%; 95% CI: 2.0-
8.9%) was identified as the predominant high-risk HPV
genotype among women with normal cytology, followed
Table 3 Odd ratios (ORs) for abnormal cytology and their
corresponding 95% confidence intervals (CIs) in HPV
positive women according to genotype classification
Total HPV
positive
women n (%)
Abnormal
cytology n (%)
OR (95% CI)
Genotype
classification£
High risk 37 (20.3) 6 (16.2) 1
Intermediate risk 5 (2.8) 0 –
Low risk 13 (7.1) 0 –
Type 81 122 (67.0) 3 (2.5) 0.13 (0.03-0.55)*
Unknown 5 (2.8) 0 –
*p-value < 0.05.
£In case of mixed HPV infection where the infecting genotypes belong to
different groups based on the above listed genotype classification categories,
infected women were placed in the category corresponding to the infecting
HPV genotype with the highest risk potential.
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HPV 45 (n = 5, (2.9%, 95% CI: 0.9-6.6%) for each) (Table 2).
For women with abnormal cytology, the most common
identified high-risk genotypes were HPV 16, HPV 18, and
HPV 56 (Table 2). For each of these genotypes, two cases
were identified (22.2% (95% CI: 2.8-60.0%) for each).
Single infection, double infections (infection with two
different HPV genotypes), and multiple infections (infec-
tion with >2 different HPV genotypes) were noted. Among
women with normal cytology, 144 (83.2%; 95% CI: 76.8-
88.5%) had single infection, 19 (11.0%; 95% CI: 6.7-16.6%)
had double infections, and 5 (2.9%; 95% CI: 0.9-6.6%) had
multiple infections (Table 2). However, in women with ab-
normal cytology, only 5 (55.6%; 95% CI: 21.2-86.3%) had
single infection, 3 (33.3%; 95% CI: 7.5-70.1%) had double
infections, and 1 (11.1%; 95% CI: 0.3-48.2%) had multiple
infections (Table 2).
Discussion
HPV is one of the most infectious and widespread sexually
transmitted diseases [17]. Nonetheless, scientific research
on HPV and other sexually transmitted infections, despite
recent progress, remains rather limited in EMENA, and is
confronted with multiple challenges [18]. This is to our
knowledge the largest cross-sectional survey describing
the prevalence of HPV infection and distribution of HPV
genotypes among Arab women from across the Arab
World, but all of whom are residing currently in the State
of Qatar.
With the advent of molecular tools, epidemiological
studies are revealing the extent of HPV infection burden
in different countries and among various clinical, ethnic,
and risk populations [19-25]. The strength of the present
study lies in the use of a standardized and sensitive mo-
lecular assay for HPV detection, rendering our findings
amenable to a detailed analysis of HPV prevalence anddistribution among general population of Arab women,
and comparison to global patterns. Such analysis is rele-
vant for planning of health service provision and devel-
opment of appropriate interventions based on the
current characteristics of the infection burden and im-
plied future trends for squamous intraepithelial lesions
and cervical cancer. The indications that HPV infection
burden might be increasing in EMENA [10], adds fur-
ther importance to this investigation.
In our study, HPV prevalence in Arab women with nor-
mal cytology was 5.8% which is comparable to state of the
art studies on representative populations in EMENA
[26-28], but overall substantially lower than other studies
from different EMENA countries on different convenient
and often not large samples [8,10,12]. Methodological dif-
ferences probably explain the differences in the measured
prevalence levels, especially so in relation to the represen-
tativeness of the tested populations. Though not based on
a probability-based sample, the large sample size in our
study, and the diverse profile of participants, facilitated a
representation of the general population of Arab women
residing in Qatar. Just as in global trends [29,30], we docu-
mented a large HPV prevalence of 18.4% in women with
cervical abnormalities, however this prevalence rate is
lower when compared to other published studies
[29,31,32]. The reasons for this deviation are unclear and
may be attributed to variations in the quality of the speci-
mens tested and the sensitivity of the HPV detection assay
used in this study [31].
The relatively low prevalence of HPV infection found
in our study is consistent with the low incidence of cer-
vical cancer in Qatar and EMENA, the lowest globally
[10,12,33]. This is also supported by the conservative
socio-cultural norms towards sexuality and the appar-
ently sparse and poorly connected nature of sexual net-
works in this part of the world [10]. The nearly universal
coverage of male circumcision in EMENA [10], with its
protective effect against HPV infection [34], may have
also contributed to a lower force of infection in the
population and reduced risk for women to acquire HPV.
However, the observed levels of prevalence suggest
that there are pockets of risks for acquiring the infection
through sexual networks that are sufficiently conducive
for sustainable propagation of this infection. These net-
works and exposure to the infection may not necessar-
ily occur in Qatar. However with the high mobility of
the population, where more than 75% of the popula-
tion are expatriates [35], and where the population
travels frequently, the infection transmission networks
are probably intersecting with sexual networks in other
countries. Based on the overall pattern of sexually trans-
mitted infections in EMENA [10,36], it is likely also that
infected women have acquired the infection from their
spouses.
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present study shows remarkably a largely flat distribu-
tion across the age groups. This contrasts with the com-
mon age-specific distribution with a sharp peak in HPV
prevalence among young women following their sexual
debut [37]. However, this result affirms the flat distribu-
tion seen recently in quality HPV prevalence studies in
EMENA [26-28]. While it is not clear why HPV preva-
lence age distribution differs in this part of the world,
the prevailing sexually conservative norms, among other
factors, may have driven differences in sexual network-
ing leading to different infection age distribution.
We found a heterogeneous distribution of HPV geno-
types, possibly due to broad geographical and cultural
range of the nationalities included in this survey. In the
present study, HPV16 was the most common genotype
followed by HPV 56, 59, 18, 45, 31, 33, 51, 58, 35, 39
and 52 among the high-risk HPV group, HPV 67 in
intermediate risk group and HPV 81,11 and 6 in the
low-risk group. This is in agreement with global studies
where HPV 16 was identified as the most common high-
risk HPV genotype [38-40]. Several studies show that
HPV 16, 18, 45, 31, 33, 52, 58, and 35, all of which were
identified in Qatar in the present study may account for
as much as 95% of cervical cancers [4,11,31,41]. In our
study, high-risk HPV genotypes were found in both
women with normal and abnormal cytology. HPV16 was
the most common high-risk genotype (4.6%) among
women with normal cytology and HPV 16 and 18 were
the most common genotypes among women with abnor-
mal cytology. When taken into consideration the fact
that HPV 16 and 18, taken together, are responsible for
about 70% of the cervical cancer cases worldwide
[4,31,41], these results suggest the need for HPV screen-
ing even in absence of cytological abnormalities and
indicate the inadequacy of cytology based assays for can-
cer screening.
In this study, HPV 81 was the most frequent low-risk
genotype among women with both normal (74%) and
abnormal (33.3%) cytology. This high HPV genotype 81
prevalence found in our study is unexpected. Though
seen in a previous study in Southern China [42], it is
possibly attributed to variations in the geographic distri-
bution of HPV genotypes and the sensitivities of differ-
ent methods used for HPV detection [42]. HPV 81 is
classified as a low-risk genotype and has not been re-
ported in high numbers in worldwide population studies,
however it is one of the most frequently observed HPV
genotypes in HIV-positive patients and is also reported
to be associated with precancerous or cancerous lesions
[32,42-46]. We also found an intratypic variant of HPV
81, which matched a unique isolate identified in an HIV-1
positive patient in India [47]. However, in this study,
women with HPV 81 genotype had a significantly reducedrisk of showing abnormal cytology than women with high-
risk genotypes, which further enforces the low-risk classifi-
cation of this HPV genotype.
In the present study, women with normal cytology
mostly had a single HPV type infection (83.2%) but in
patients with cytological abnormalities, infection with
double and multiple HPV types were observed fre-
quently (44.4%), which is similar with previous reports
where multiple HPV infection with high-risk genotypes
have found to be associated with a significantly increased
risk of cervical intraepithelial neoplasia compared to in-
fection with a single HPV type [48,49].
In this study, we recruited women attending hospitals
for routine gynecological care/ clinical symptoms while
excluding known cervical cancer patients to analyze
HPV prevalence across a diverse range of women, how-
ever as all these women were patients, this population
may not be completely representative of the general
women population in Qatar. With only married/previ-
ously married women being included and no sexual be-
havior measures being collected as part of the study, due
to the sensitivity of sexual behavior in this region, we
were unable to examine specific risk factors for the in-
fection. Another complication is the high rates of inter-
marriage between different nationalities and change in
the nationality status of the women after marriage,
which may bias the nationality specific HPV prevalence
in this study.
Conclusion
In conclusion, our study showed a relatively low preva-
lence (6.1%) of HPV infection in comparison to Western
countries and presence of a varied genotypic profile of
HPV with a high prevalence of low-risk HPV genotype
81 among general population of Arab women residing in
Qatar. Though lower than in other countries and re-
gions, our study suggests that there is sufficient infection
burden to warrant public health interventions. HPV vac-
cination should be considered as a prevention interven-
tion for girls as well as women in Qatar. The low levels
of Pap smear screening in Qatar [50], just as in most
EMENA countries [10,51], adds another reason to for
HPV vaccination programs. This is also supported by a
positive attitude towards HPV vaccination in at least few
Muslim societies [52]. Though a cost-effectiveness ana-
lysis is yet to be conducted, based on analyses in other
countries with some similarity in context [53,54], vaccin-
ation may offer a cost-effective method to reduce cervical
cancer and its mortality. When considering a prophylactic
vaccine, the data from this study show that the currently
used quadrivalent vaccine “GARDASIL” (Merck & Co.,
Inc. USA) has the potential to prevent HPV infections in
Arab women. However, as differences were noted in our
study population with a high prevalence of HPV 81 and
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such as HPV 56, 59, 45 and 67, the potential for cancer
prevention in this region may rise if these frequent high
and intermediate risk HPV genotypes, and possibly HPV
81, are also included in future HPV vaccines targeting this
specific population.
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